I am bullish on Oscar Health (OSCR) due to its efficient D2C model, AI integration, and improving EBITDA margins despite high revenue growth. OSCR's opportunity in the ICHRA market is significant, with projections to increase 3x-5x by 2030, positioning it well against larger competitors. Risks include potential changes to ACA subsidies under future administrations, which could disrupt OSCR's current business model and force a shift to ICHRA.
NEW YORK--(BUSINESS WIRE)--Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE: OSCR), Ryan Fukushima, COO of Tempus,.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.